Ellen Lubman, MBA

Ellen Lubman served as Werewolf’s Chief Business Officer from August 2020 to April 2025. From October 2018 to July 2020, Ellen served as the Chief Business Officer at Impel NeuroPharma, Inc., a publicly traded biotechnology company focused on neurological diseases. Prior to Impel, she was the Vice President of External Science & Innovation at Forest Labs, from February 2014 until its acquisition by Actavis plc in July 2014, and served in the same role at Actavis through June 2018 during which time Actavis merged with and renamed itself Allergan plc. Prior to Allergan, Ellen held numerous executive and leadership roles at Kadmon Pharmaceuticals, Bristol Myers Squibb, Celtic Pharma Management, L.P., Robertson Stephens Investment Bank and Abbott Labs. She has served on the board of directors of Reunion Neuroscience, Inc., a publicly traded biotechnology company, since June 2021 and on the board of Cytovation ASA. Ellen serves on the Advisory Board of TMRW.org and Aronora Inc. She also currently serves the board of directors of Red Door Community in NYC. Ellen earned her MBA from Stanford Graduate School of Business in Global Management.